Metabolic syndrome and masked hypertension among African Americans: The Jackson Heart Study

Journal of Clinical Hypertension

Volumn 19, Issue 6, 2017, Pages 592-600

  Colantonio, Lisandro D ^a   Anstey, D Edmund ^b   Carson, April P ^a   Ogedegbe, Gbenga ^c   Abdalla, Marwah ^b   Sims, Mario ^d   Shimbo, Daichi ^b   Muntner, Paul ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; HIGH DENSITY LIPOPROTEIN;

ABDOMINAL OBESITY; ADULT; AFRICAN AMERICAN; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MASKED HYPERTENSION; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CIRCADIAN RHYTHM; COMPLICATION; ETHNOLOGY; HYPERCHOLESTEROLEMIA; HYPERTENSION; MISSISSIPPI; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RISK FACTOR; UNITED STATES;

AFRICAN AMERICANS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIOVASCULAR DISEASES; CIRCADIAN RHYTHM; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPOPROTEINS, HDL; MALE; MASKED HYPERTENSION; METABOLIC SYNDROME; MIDDLE AGED; MISSISSIPPI; OBESITY, ABDOMINAL; PREVALENCE; RISK FACTORS; TRIGLYCERIDES; UNITED STATES;

EID: 85013015621     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12974     Document Type: Article

References (45)

1. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645.
2. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. JAMA. 2015;313:1973–1974.
3. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167–174.
4. Ferrara LA, Cardoni O, Mancini M, Zanchetti A. Metabolic syndrome and left ventricular hypertrophy in a general population. Results from the Gubbio Study. J Hum Hypertens. 2007;21:795–801.
5. McNeill AM, Rosamond WD, Girman CJ, et al. Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). Am J Cardiol. 2004;94:1249–1254.
6. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care. 2005;28:385–390.
7. Beltran-Sanchez H, Harhay MO, Harhay MM, McElligott S. Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010. J Am Coll Cardiol. 2013;62:697–703.
8. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414–419.
9. Suzuki T, Voeks J, Zakai NA, et al. Metabolic syndrome, C-reactive protein, and mortality in U.S. Blacks and Whites: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Diabetes Care. 2014;37:2284–2290.
10. Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009;54:226–232.
11. Cuspidi C, Sala C, Tadic M, Rescaldani M, Grassi G, Mancia G. Untreated masked hypertension and subclinical cardiac damage: a systematic review and meta-analysis. Am J Hypertens. 2015;28:806–813.
12. Stergiou GS, Asayama K, Thijs L, et al. Prognosis of white-coat and masked hypertension: international database of home blood pressure in relation to cardiovascular outcome. Hypertension. 2014;63:675–682.
13. Pierdomenico SD, Lapenna D, Bucci A, et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens. 2005;18:1422–1428.
14. Hanninen MR, Niiranen TJ, Puukka PJ, Jula AM. Metabolic risk factors and masked hypertension in the general population: the Finn-Home study. J Hum Hypertens. 2014;28:421–426.
15. Asayama K, Sato A, Ohkubo T, et al. The association between masked hypertension and waist circumference as an obesity-related anthropometric index for metabolic syndrome: the Ohasama study. Hypertens Res. 2009;32:438–443.
16. Taylor HA Jr, Wilson JG, Jones DW, et al. Toward resolution of cardiovascular health disparities in African Americans: design and methods of the Jackson Heart Study. Ethn Dis. 2005;15:S6-4-17.
17. Thijs L, Hansen TW, Kikuya M, et al. The International Database of Ambulatory Blood Pressure in relation to Cardiovascular Outcome (IDACO): protocol and research perspectives. Blood Press Monit. 2007;12:255–262.
18. Dubbert PM, Carithers T, Ainsworth BE, Taylor HA Jr, Wilson G, Wyatt SB. Physical activity assessment methods in the Jackson Heart Study. Ethn Dis. 2005;15:S6-56-61.
19. Abdalla M, Booth JN 3rd, Seals SR, et al. Masked hypertension and incident clinic hypertension among blacks in the Jackson Heart Study. Hypertension. 2016;68:220–226.
20. Carpenter MA, Crow R, Steffes M, et al. Laboratory, reading center, and coordinating center data management methods in the Jackson Heart Study. Am J Med Sci. 2004;328:131–144.
21. Jackson Heart Study Protocol, Manual 4, Blood Pressure, Visit 1 (Version 1.0). Jackson MS: Jackson Heart Study Coordinating Center; 2001. [Cited: November 19, 2016]. Available in: https://www.jacksonheartstudy.org/Portals/0/pdf/manuals1/Blood_pressure_manual4_02-18-2001(1).pdf.
22. Pickering TG, White WB. When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens. 2008;2:119–124.
23. Axelson O, Fredriksson M, Ekberg K. Use of the prevalence ratio v the prevalence odds ratio as a measure of risk in cross sectional studies. Occup Environ Med. 1994;51:574.
24. Coutinho LM, Scazufca M, Menezes PR. Methods for estimating prevalence ratios in cross-sectional studies. Rev Saude Publica. 2008;42:992–998.
25. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30:377–399.
26. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393.
27. Pierdomenico SD, Cuccurullo F. Ambulatory blood pressure monitoring in type 2 diabetes and metabolic syndrome: a review. Blood Press Monit. 2010;15:1–7.
28. Schillaci G, Pirro M, Vaudo G, et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol. 2004;43:1817–1822.
29. Mancia G, Bombelli M, Corrao G, et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension. 2007;49:40–47.
30. Pierdomenico SD, Lapenna D, Di Tommaso R, et al. Prognostic relevance of metabolic syndrome in hypertensive patients at low-to-medium risk. Am J Hypertens. 2007;20:1291–1296.
31. Leoncini G, Ratto E, Viazzi F, et al. Metabolic syndrome and ambulatory arterial stiffness index in non-diabetic patients with primary hypertension. J Hum Hypertens. 2007;21:802–807.
32. Sheppard JP, Fletcher B, Gill P, Martin U, Roberts N, McManus RJ. Predictors of the home-clinic blood pressure difference: a systematic review and meta-analysis. Am J Hypertens. 2016;29:614–625.
33. Redmond N, Booth JN 3rd, Tanner RM, et al. Prevalence of masked hypertension and its association with subclinical cardiovascular disease in African Americans: results from the Jackson Heart Study. J Am Heart Assoc. 2016;5:e002284.
34. Viera AJ, Lin FC, Tuttle LA, et al. Levels of office blood pressure and their operating characteristics for detecting masked hypertension based on ambulatory blood pressure monitoring. Am J Hypertens. 2015;28:42–49.
35. Booth JN 3rd, Muntner P, Diaz KM, et al. Evaluation of criteria to detect masked hypertension. J Clin Hypertens (Greenwich). 2016;18:1086–1094. doi:10.1111/jch.12830
36. Shimbo D, Newman JD, Schwartz JE. Masked hypertension and prehypertension: diagnostic overlap and interrelationships with left ventricular mass: the Masked Hypertension Study. Am J Hypertens. 2012;25:664–671.
37. Banegas JR, Ruilope LM, de la Sierra A, et al. High prevalence of masked uncontrolled hypertension in people with treated h ypertension. Eur Heart J. 2014;35:3304–3312.
38. Bromfield SG, Shimbo D, Bertoni AG, Sims M, Carson AP, Muntner P. Ambulatory blood pressure monitoring phenotypes among individuals with and without diabetes taking antihypertensive medication: the Jackson Heart Study. J Hum Hypertens. 2016;30:731–736. doi:10.1038/jhh.2016.1027.
39. Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United States: national health and nutrition examination survey, 2011-2012. NCHS Data Brief. 2013;(133):1–8.
40. Carson AP, Howard G, Burke GL, Shea S, Levitan EB, Muntner P. Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis. Hypertension. 2011;57:1101–1107.
41. Howard VJ, Kleindorfer DO, Judd SE, et al. Disparities in stroke incidence contributing to disparities in stroke mortality. Ann Neurol. 2011;69:619–627.
42. Movahed MR, John J, Hashemzadeh M, Jamal MM, Hashemzadeh M. Trends in the age adjusted mortality from acute ST segment elevation myocardial infarction in the United States (1988-2004) based on race, gender, infarct location and comorbidities. Am J Cardiol. 2009;104:1030–1034.
43. United States Renal Data System. Incidence, Prevalence, Patient Characteristics, and Treatment Modalities. 2015 USRDS annual data report: Epidemiology of Kidney Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2015.
44. Booth JN 3rd, Diaz KM, Seals SR, et al. Masked hypertension and cardiovascular disease events in a prospective cohort of blacks: the Jackson Heart Study. Hypertension. 2016;68:501–510.
45. Diaz KM, Veerabhadrappa P, Brown MD, Whited MC, Dubbert PM, Hickson DA. Prevalence, determinants, and clinical significance of masked hypertension in a population-based sample of African Americans: the Jackson Heart Study. Am J Hypertens. 2015;28:900–908.